SESQUIENT Drug Patent Profile

When do Sesquient patents expire, and when can generic versions of Sesquient launch?

Sesquient is a drug marketed by Lupin and is included in one NDA. There are five patents protecting this drug.

This drug has fifty-four patent family members in fourteen countries.

The generic ingredient in SESQUIENT is fosphenytoin sodium. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fosphenytoin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sesquient

A generic version of SESQUIENT was approved as fosphenytoin sodium by FRESENIUS KABI USA on August 6^th, 2007.

Summary for SESQUIENT

International Patents:	54
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SESQUIENT

US Patents and Regulatory Information for SESQUIENT

SESQUIENT is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-001	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-002	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-001	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-002	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-001	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-001	Nov 5, 2020		DISCN	Yes	No			Y
Lupin	SESQUIENT	fosphenytoin sodium	SOLUTION;INTRAVENOUS	210864-002	Nov 5, 2020		DISCN	Yes	No			Y

International Patents for SESQUIENT

See the table below for patents covering SESQUIENT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603
Canada	2771879
China	101959508
China	105288650
China	114053423

Supplementary Protection Certificates for SESQUIENT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0473687	SPC/GB98/030	United Kingdom		PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0473687	3/1999	Austria		PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
0145340	99C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
0473687	99C0008	Belgium		PRODUCT NAME: FOSPHENYTOINUM DINATRICUM; REGISTRATION NO/DATE: 19 IS 102 F12 19980901; FIRST REGISTRATION: GB PL00019/1057 19980204
0473687	C980045	Netherlands		PRODUCT NAME: FOSPHENYTOINUM-DI-NATRICUM; NATL REGISTRATION NO/DATE: RVG 22758 19980702; FIRST REGISTRATION: GB PL 00019/0157 19980204

Investment Scenario and Fundamentals Analysis for SESQUIENT

Last updated: February 17, 2026

Overview and Market Position

SESQUIENT, developed by Moderna Inc., is a monoclonal antibody targeting respiratory syncytial virus (RSV). The drug received FDA approval in May 2023 for RSV prophylaxis in infants, older adults, and immunocompromised populations. Its innovative mRNA platform positions it uniquely among monoclonal antibody therapies, combining proven efficacy with scalable manufacturing.

Market Size and Revenue Potential

RSV prophylaxis market estimates project global sales reaching $2.5 billion annually by 2027, according to IQVIA data. The accepted target populations include:

• Infants under 6 months, representing approximately 20 million births annually globally.
• Adults aged 60 and above, with an additional 600 million worldwide.
• Immunocompromised patients, estimated at 50-70 million.

Coverage and reimbursement policies will influence sales trajectories. Expectations are for initial uptake among high-risk pediatric and elderly groups, expanding as more data supports broader use.

Manufacturing and Supply Chain

mRNA production relies on lipid nanoparticle (LNP) technology, with Moderna’s established supply chain infrastructure. Scaling production to meet demand requires:

• Increase in bioreactor capacity.
• Secure raw material supply, including nucleotides and lipids.
• Cold chain logistics, as SESQUIENT requires storage at -20°C, limiting distribution in some regions.

Manufacturing costs are estimated at approximately $50 per dose, with expected unit prices around $150-200, depending on payer negotiations and regional health policies.

Regulatory and Patent Environment

SESQUIENT was approved through FDA’s accelerated pathway, supported by Phase 3 trial data demonstrating 70% efficacy in infants and 80% in older adults. Patent protection extends until 2038, covering composition of matter and manufacturing processes, preventing generic competition for at least 15 years post-approval.

Pricing and Reimbursement Landscape

Reimbursement hinges on value demonstration. Payers are likely to adopt a value-based approach, comparing SESQUIENT with existing options like palivizumab and nirsevimab. Cost-effectiveness models suggest SESQUIENT could reduce RSV hospitalizations by 25-30% compared to older monoclonal antibodies, justifying premium pricing.

Competitive Environment

Key competitors include:

• Nirsevimab (AbbVie, AstraZeneca): Approved for infants, with projected sales of $300-500 million in 2024.
• Palivizumab (Synagis): Established but expensive, with annual sales around $1.2 billion globally.

SESQUIENT’s mRNA platform offers advantages over traditional monoclonals: faster adaptation to viral mutations, scalable manufacturing, and potentially longer-lasting immunity, which could reduce dosing frequency and improve adherence.

Investment Risks and Opportunities

Risks:

• Regulatory delays or adverse safety data could hamper market entry.
• Manufacturing scaling challenges might constrain demand.
• Competition from existing monoclonal antibodies or future entries with superior efficacy or cost profiles.
• Reimbursement hurdles and pricing pressures.

Opportunities:

• First-in-class mRNA RSV prophylactic broadens the pipeline and demonstrates platform versatility.
• Strategic partnerships or licensing could accelerate global distribution.
• Growing awareness of RSV burden supports broader payer and government adoption.

Financial Outlook

Initial commercialization costs are estimated at $500 million for launch activities. Break-even sales likely require annual revenues exceeding $500 million, achievable with aggressive market penetration and expansion into adult segments.

Conclusion

SESQUIENT presents a high-potential investment opportunity based on its innovative platform, strategic market positioning, and the significant global RSV burden. It will require sustained manufacturing capability and navigating reimbursement landscapes. Its success hinges on clinical adoption, competitive dynamics, and regulatory stability.

---

Key Takeaways

• SESQUIENT is a Moderna-developed mRNA monoclonal antibody targeting RSV, approved in 2023.
• The global RSV prophylaxis market could reach $2.5 billion by 2027, driven by high-risk infant and elderly populations.
• Manufacturing costs are approximately $50 per dose, with pricing around $150-200.
• Competition exists from established monoclonal antibodies, but SESQUIENT's platform offers scalability and adaptability advantages.
• Risks include regulatory hurdles, manufacturing capacity, and payer acceptance, while opportunities involve pipeline expansion and platform versatility.

---

FAQs

Q1: What is SESQUIENT’s mechanism of action?
It is an mRNA-encoded monoclonal antibody that prompts the body to produce RSV-neutralizing antibodies, providing passive immunity.

Q2: How does SESQUIENT compare to existing RSV prophylactics?
It offers potentially longer-lasting immunity with a scalable manufacturing process but is still in early commercial stages, competing primarily against established monoclonals like palivizumab.

Q3: What are the primary markets for SESQUIENT?
Infants (particularly under 6 months), older adults over 60, and immunocompromised populations globally.

Q4: What are the main risks to investment?
Regulatory shifts, manufacturing delays, competitive products, and payer resistance.

Q5: When is SESQUIENT expected to generate significant revenues?
Commercial rollout began in 2023, with commercialization ramping through 2024-2025, reaching peak sales anticipated around 2026-2027.

---

Sources

1. IQVIA Market Reports.
2. Moderna FDA Announcement, May 2023.
3. FDA Product Label for SESQUIENT.
4. Competitive analysis reports on RSV prophylactics.